



News Updates: April 10, 2014

Party Manifestoes

Publication: Mint

Edition: Online

Date: April 10, 2014

Headline: [EC now says it can't enforce its guidelines on manifestos](#)

Synopsis: The Election Commission of India (EC) has admitted that it will not be able to scrutinize manifestos and act against political parties that have not disclosed the financial implications and fiscal burden of their promises—something it had highlighted in an earlier order. Over the past month, all parties have released their manifestos with great fanfare, but none have charted out the fiscal roadmap for their big-ticket promises. While the Congress promised the right to health, pension and housing for all, broadband connectivity to 2.5 lakh villages, and training for 100 million jobs, the main opposition Bharatiya Janata Party (BJP) promised the creation of a price stabilization fund to combat inflation, water to every farm and a low-cost housing programme. New entrant Aam Aadmi Party (AAP), too, promised health and education for all.

Similar reports in-

Daily News & Analysis- [Lok Sabha elections 2014: The anatomy of the election manifesto](#)

The Asian Age- [The mystical manifesto](#)

Daily News & Analysis- [Vote for Congress to save India: Sonia Gandhi](#)

Acquisition deals

Publication: The Economic Times

Edition: National

Date: April 10, 2014

Headline: [Ensure Sun Pharma-Ranbaxy deal doesn't create monopoly: Experts to CCI](#)

Synopsis: The Competition Commission of India (CCI) will have its hands full in the coming months with Sun Pharmaceutical announcing its acquisition of Ranbaxy Laboratories and the global merger plans of France's Lafarge and Switzerland's Holcim. Experts believe that both the deals should be scrutinised by the competition regulator as these companies have significant assets in India. "In the case of Sun Pharmaceuticals and Ranbaxy, the thresholds will be high enough to fall" under CCI's ambit, said Manas Kumar Chaudhari, partner, Khaitan & Co.

Similar reports in-

Mint- [Sun Pharma to retain Ranbaxy brand wherever it's strong](#)

The Financial Express- [The DNA of Ranbaxy Laboratories Ltd lives on... We have a perfect fit, says Sun Pharma chairman](#)

The Hindu Business Line- [Sun Pharma defends Ranbaxy deal, rejects insider trading claims](#)

Business Today- [Ranbaxy's reputation related issues will solve themselves: Sun Pharma Chairman](#)

Business Standard- [Job cut worry for Ranbaxy sales team](#)

Publication: Business Standard

Edition: National

Date: April 10, 2014

Headline: [Torrent Pharma hits record high as CCI clears Elder Pharma deal](#)

Synopsis: Torrent Pharmaceuticals has rallied nearly 9% to Rs 608, its record high on the BSE, on report that Competition Commission of India (CCI) has approved the company's proposed Rs 2,000 crore acquisition of Elder Pharma's formulations business in India and Nepal.

Similar reports in-

The Economic Times- [Torrent Pharma rallies over 8%, hits 52-week high as CCI clears Elder Pharma deal](#)

The Times of India- [CCI clears Torrent-Elder Pharma deal](#)

The Financial Express- [CCI clears Torrent-Elder Pharma Rs 2,000 crore deal](#)

Drug pricing/ Access

Publication: The Hindu

Edition: Delhi

Date: April 10, 2014

Headline: WHO joins clamour to make new hepatitis C pills affordable (link unavailable, scan attached)

Synopsis: The World Health Organization wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

Similar reports in-

Reuters- [WHO joins clamor to make new hepatitis C pills affordable](#)

Bloomberg Businessweek- [WHO Calls for 'Concerted Effort' to Lower Hepatitis C Drug Cost](#)

General Industry

Publication: The Economic Times

Edition: National

Date: April 10, 2014

Headline: [Pharma MNCs may need new prescription for growth here](#)

Synopsis: Sun Pharmaceutical's acquisition of Ranbaxy Laboratories, the largest consolidation move in the Indian market, may force multinational pharmaceutical companies to change their strategy considering that the combined entity will become the country's largest drug maker and the fifth largest generic company in the world. It will command a turnover of \$4 billion globally while in India it will have estimated sales of Rs 6,921 crore.

Publication: The Economic Times

Edition: Online

Date: April 10, 2014

Headline: [Lupin gets USFDA approval for diabetes management drug](#)

Synopsis: Lupin today said it has received final approval from the US health regulator to sell generic diabetes management drug Pioglitazone Tablets in the American market. Lupin said its US subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market generic version of Takeda Pharmaceuticals USA Inc's Actos tablets.

Similar reports in-

Business Standard- [Lupin inches up after USFDA nod for a generic medicine](#)

Daily News & Analysis- [Lupin gets USFDA approval for generic diabetes drug](#)

Publication: The Pharma Times

Edition: Online

Date: April 8, 2014

Headline: [Pharma business model must change radically: KPMG](#)

Synopsis: Pharmaceutical companies need to stop simply paying lip-service to patients and radically alter their business models if they are to meet increasing global demand while improving patient outcomes, says KPMG. The sector's return on R&D expenditure has fallen in 20 years from an industry average of around 20% to 10%, new research from the advisory firm shows. Together with dramatically falling price-earnings ratios across the industry, this explains why investors are attributing less value to companies' product pipelines, it says.